Watching the availability and use of rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT)

Malaria Journal

Commentary

Thomas P. Eisele¹  Richard W. Steketee² 

[1] Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA;Malaria Control and Elimination Partnership in Africa (MACEPA), PATH, Seattle, WA, USA;

关键词: Malaria;    Malaria Elimination;    Artemether;    Lumefantrine;    Malaria Case Management;   

DOI  :  10.1186/s12936-017-1821-0

 received in 2017-04-12, accepted in 2017-04-13,  发布年份 2017

来源: Springer

【 摘 要 】

At the turn of this new century and after much debate, the malaria community reckoned with failing first line therapies and moved to a global recommendation for deployment of an artemisinin-based combination therapy (ACT) to treat infections due to Plasmodium falciparum. No one said it was going to be easy. This series in the Malaria Journal reports longitudinal snapshots of how the core pillar of malaria elimination of ensuring universal access to malaria diagnosis and treatment is faring—it is safe to say “not so well”. Core issues that must be addressed to ensure universal access to diagnosis and treatment, and achieve elimination, include lack of access to these essential services for those with malaria and the lack of a common effective service delivery approach to ensure high quality diagnosis and treatment, especially in the private sector which provides the bulk of malaria case management services in many settings. The barriers to universal access to high quality diagnosis and treatment for malaria will need to be addressed if malaria elimination is to remain a real possibility in the foreseeable future.

【 授权许可】

CC BY   
© The Author(s) 2017